Jan Diekmann

Company: BioNTech

Job title: Senior Director Non-clinical Safety

Seminars:

Preclinical Safety Evaluation of mRNA Cancer Therapeutics: A Platform Approach 2:30 pm

Toxicology assessment of RNA-therapeutics can be split into two parts – assessment of RNA-LNP characteristics and the assessment of translated protein Toxicity data of an RNA-LNP platform facilitating various RNA payloads show a comparable safety profile in non-clinical safety studies Platform-based strategy could reduce the need for toxicity tests involving animal testing (3R)Read more

day: Day One